| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$19.6M | ROE | −88.60% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $82.7M | Trading Days | 1070 |
| 52W High | 3.83 |
| 52W Low | 0.55 |
| % Off High | −75.89% |
| YTD | −31.59% | 1Y | 29.16% |
| 3Y | −45.99% | Since incept. (ann.) | −41.73% |
| Ann. Volatility (1Y) | 130.27% | Ann. Volatility (3Y) | 119.90% |
| Sharpe (1Y) | 0.85 | Sharpe (3Y) | 0.43 |
| Max Drawdown (1Y) | −81.30% | Max Drawdown (3Y) | −90.88% |
| Beta (3Y, vs SPY) | 1.86 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | $79.5M | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $76.8M | 16.8 |
| PROK | PROKIDNEY CORP. | $94.8M | — |
| PTHS | Pelthos Therapeutics Inc. | $96.5M | — |
| ATRA | Atara Biotherapeutics, Inc. | $70.4M | 3.0 |
| TCRX | TScan Therapeutics, Inc. | $100.4M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.9M | 4.5 |
| LONA | LeonaBio, Inc. | $65.5M | — |
| OTLK | Outlook Therapeutics, Inc. | $109.3M | — |
| VXRT | Vaxart, Inc. | $116.1M | 6.9 |
| ENGN | enGene Therapeutics Inc. | $117.9M | 0.8 |
| Scilex Holding Co |
| $57.9M |
| — |
